Stay updated with breaking news from Compass Pathways. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Unlock the Potential: Dive into the Future of Psychedelic Healthcare Investments with Compass Pathways (CMPS). As Big Pharma Takes Notice, Citadel Advisors Secures a 4.9% Stake. Positive Phase II Trial Results Propel CMPS Towards a Psychological Trigger at $10. Explore the Playbook Unfolding in the Psychedelic Industry. #PsychedelicInvesting #CMPS #HealthcareStocks
Series A funding raises more than $100 million for MAPS amid a flurry of deals by competitors
Biotechnology company Compass Pathways plc CMPS and Greenbrook TMS Inc GBNH have entered into a three-year research collaboration agreement to explore…
Biotechnology company Compass Pathways plc (NASDAQ: CMPS) and Greenbrook TMS Inc (NASDAQ: GBNH) have entered into a three-year research collaboration agreement to explore delivery models